Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.clim.2020.108555 http://scihub22266oqcxt.onion/10.1016/j.clim.2020.108555 32771488!7410014!32771488     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Immunol 2020 ; 219 (ä): 108555 Nephropedia Template TP {{tp|p=32771488|t=2020. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19 |pdf=|usr=}}{{32771488}} gab.com Text Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19 JO: Clin Immunol http://www.kidney.de/pget.php?&tw=1&pmid=32771488 #FOAvip Respiratory failure and acute kidney injury (AKI) are associated with high mortality in SARS-CoV-2-associated Coronavirus disease 2019 (COVID-19). These manifestations are linked to a hypercoaguable, pro-inflammatory state with persistent, systemic complement activation. Three critical COVID-19 patients recalcitrant to multiple interventions had skin biopsies documenting deposition of the terminal complement component C5b-9, the lectin complement pathway enzyme MASP2, and C4d in microvascular endothelium. Administration of anti-C5 monoclonal antibody eculizumab led to a marked decline in D-dimers and neutrophil counts in all three cases, and normalization of liver functions and creatinine in two. One patient with severe heart failure and AKI had a complete remission. The other two individuals had partial remissions, one with resolution of his AKI but ultimately succumbing to respiratory failure, and another with a significant decline in FiO(2) requirements, but persistent renal failure. In conclusion, anti-complement therapy may be beneficial in at least some patients with critical COVID-19. Twit Text FOAVip Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19 ????Clin Immunol http://www.kidney.de/pget.php?&tw=1&pmid=32771488 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32771488 #FOAvip English Wikipedia <ref>{{Cite pmid|32771488}}</ref> Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19 #MMPMID32771488 Laurence J; Mulvey JJ; Seshadri M; Racanelli A; Harp J; Schenck EJ; Zappetti D; Horn EM; Magro CM Clin Immunol 2020[Oct]; 219 (ä): 108555 PMID32771488show ga Respiratory failure and acute kidney injury (AKI) are associated with high mortality in SARS-CoV-2-associated Coronavirus disease 2019 (COVID-19). These manifestations are linked to a hypercoaguable, pro-inflammatory state with persistent, systemic complement activation. Three critical COVID-19 patients recalcitrant to multiple interventions had skin biopsies documenting deposition of the terminal complement component C5b-9, the lectin complement pathway enzyme MASP2, and C4d in microvascular endothelium. Administration of anti-C5 monoclonal antibody eculizumab led to a marked decline in D-dimers and neutrophil counts in all three cases, and normalization of liver functions and creatinine in two. One patient with severe heart failure and AKI had a complete remission. The other two individuals had partial remissions, one with resolution of his AKI but ultimately succumbing to respiratory failure, and another with a significant decline in FiO(2) requirements, but persistent renal failure. In conclusion, anti-complement therapy may be beneficial in at least some patients with critical COVID-19. |Acute Kidney Injury/complications/drug therapy/*immunology/virology[MESH] |Adult[MESH] |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |Betacoronavirus/immunology/*pathogenicity[MESH] |Biomarkers/metabolism[MESH] |COVID-19[MESH] |Complement Activation/drug effects[MESH] |Complement C4b/antagonists & inhibitors[MESH] |Complement C5/antagonists & inhibitors[MESH] |Complement Inactivating Agents/*therapeutic use[MESH] |Complement Membrane Attack Complex/antagonists & inhibitors[MESH] |Coronavirus Infections/complications/drug therapy/*immunology/virology[MESH] |Cytokine Release Syndrome/complications/drug therapy/*immunology/virology[MESH] |Female[MESH] |Fibrin Fibrinogen Degradation Products/metabolism[MESH] |Humans[MESH] |Immunity, Humoral/drug effects[MESH] |Male[MESH] |Mannose-Binding Protein-Associated Serine Proteases/genetics/immunology[MESH] |Middle Aged[MESH] |Neutrophils/immunology/pathology[MESH] |Pandemics[MESH] |Peptide Fragments/antagonists & inhibitors[MESH] |Pneumonia, Viral/complications/drug therapy/*immunology/virology[MESH] |SARS-CoV-2[MESH]Anti-complement C5 therapy with eculizumab in three cases of critical (epmc).pdf DeepDyve Pubget Overpricing